Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
The access information for the investor conference call is as follows:
Direct Toll / International – 1-(866) 831-8711
Domestic US/Canada - 1-(203) 518-9883
Program Title: Generex Biotechnology Conference Call
Conference ID – 89636
- FDA response to Pre-IND briefing package for Ii-Key-SARS-CoV-2 vaccine
- Meeting with the Canadian National Research Council to discuss moving the Ii-Key-SARS-CoV-2 vaccine technology forward
- $20 Million Non-binding Memorandum of Understanding completed with an investor for a strategic upmarket transaction
- $10 Million financing proposal in the same MOU for the acquisition of infectious disease and cancer diagnostics company awaiting EUA approval from FDA for COVID-19 rapid diagnostic assay system
- ALTuCell acquisition update
- NuGenHealth SaaS Remote Patient Monitoring and Chronic Care Management 50% Partnership
- Completed a Non-Binding Memorandum of Understanding Regarding Development partnership for Ii-Key-SARS-CoV-2 in Malaysia worth up to $150 Million
MIRAMAR, Fla., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the call in information and an updated agenda for the shareholder conference call on Wednesday, August 26th at 9:30 am.
During the call, Generex President & CEO Joe Moscato will discuss the previously published agenda as well as new developments with the COVID-19 vaccine program.
On August 24th, the FDA delivered a written response to Generex’ Pre-IND briefing package for the Ii-Key-SARS-CoV-2 vaccine in which they have agreed to the overall clinical plan and provided straight-forward guidance on protocol specifics and vaccine product data requests that will be addressed in the IND (investigational new drug) submission.
Additionally, Generex has been assigned a Lead Industrial Technology Advisor (ITA) at the Canadian Research Council with whom the company is meeting in the coming days to discuss opportunities to move the Ii-Key technology forward for the development of a SARS-CoV-2 vaccine in Canada.
Mr. Moscato said, “This is an exciting time for Generex as we advance a number of our corporate initiatives to realize our goal of building shareholder value through the development of our technologies, the acquisition of strategic partners, and the implementation of technology to engage patients in telehealth solutions. We are pleased with the responses we just recently received from FDA and from the Canadian Research Council to advance our Ii-Key-SARS-CoV-2 vaccine, and I look forward to sharing details with shareholders tomorrow.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with te Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Biotechnology Corporation
1-800-391-6755 Extension 222
Upcoming Life Sciences Events
- November 2020
- Precision in Clinical Trials Summit San Francisco
- Precision in Drug Discovery & Preclinical Summit
- Precision in Medical Devices Summit San Francisco